The prior approved label claim allowed Intercept treatment only within eight hours of blood collection. This new extended treatment window applies to plasma from single donor apheresis and
Almost all existing investors are participating in this round, including Abingworth, Bio One/Singapore, Charter Ventures, HBM BioVentures, JAIC America, Menlo Ventures, Pac-Link Ventures, Saints Capital and Sightline Ventures.
The granted family of patents covers the anti-cyclic citrullinated peptides (CCP) test offered by Axis-Shield and its commercial partners and, with similar patents in Europe and the US,
Avi plans to conduct the trial as part of its continued collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID). Preclinical results of AVI-6002 demonstrated
The companies filed this lawsuit under the Hatch-Waxman Act in response to the notice from Upsher-Smith of its filing of an abbreviated new drug application with the FDA
Under the terms of the agreement ZBx is entitled to a nine-month exclusive evaluation period to determine the feasibility of incorporating Ambrilia’s PSP94 technology for prostate cancer into
The Phase I randomized, double-blind, placebo-controlled study for ALKS 33 will enroll 16 healthy volunteers and is designed to assess the pharmacokinetics, safety and tolerability of ALKS 33
Within the frame of the collaboration, AliX will provide Sosho with its protein engineering expertise and Sosho will apply its crystallization technology. Sosho is using femto-second laser irradiation
The FDA indicated in its letter that it cannot approve the application for oritavancin in its current form and will require Targanta to perform an additional well-controlled clinical
This highly sensitive test offers Roche’s fully automated real-time polymerase chain reaction (PCR) technology to achieve a broad range for the quantitative detection of hepatitis B virus DNA
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.